Stock Price & Analysis

The S1 support level for CSTL Stock is $24.7 ,The R1 resistant level for CSTL Stock is $28.1.

As of the end of day on 2025-01-30, the price of CSTL Stock was $28.2.

The target price for CSTL Stock according to analyst rating is 40.17, with the highest price target at 44.00 and the lowest at 36.00. Analysts have a Strong Buy rating on CSTL Stock overall.

The market cap of CSTL is $790.4M.

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

CSTL has a total of 610 employees.